Photocure ASA released its earnings results on Feb 18, 2026. The company reported -$0.031 earnings per share for the quarter, missing the consensus estimate of -$0.03 by -$0.001.

Is Photocure ASA overvalued?

According to Wall Street analysts Photocure ASA’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Photocure ASA pay dividends?

Photocure ASA does not currently pay dividends.

What is Photocure ASA’s EPS estimate?

Photocure ASA’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Photocure ASA have?

Photocure ASA has 27,120,820 shares outstanding.

What happened to Photocure ASA’s price movement after its last earnings report?

Photocure ASA reported an EPS of -$0.031 in its last earnings report, missing expectations of -$0.03. Following the earnings report the stock price went up 0.922%.

Which hedge fund is a major shareholder of Photocure ASA?

Currently, no hedge funds are holding shares in PHCUF

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Photocure ASA

Photocure ASA, a specialty pharmaceutical company, engages in the research, development, production, distribution, marketing, and sale of pharmaceutical products in Nordic countries, Germany, France, Austria, the United Kingdom, the Netherlands, Italy, other European Countries, and the United States. The company offers Hexvix/Cysview for the detection and management of bladder cancer. It also develops Cevira for the treatment of human papilloma virus infection and precancerous lesions of the cervix. The company sells its products to pharmaceutical wholesalers, pharmacies, and hospitals through license partners. Photocure ASA was founded in 1993 and is headquartered in Oslo, Norway.

Photocure ASA (PHCUF) Earnings & Revenues

Historic Earnings Reports

PHCUF Company Deck

PHCUF Earnings Call

Q4 2026

0:00 / 0:00

Earnings Call Sentiment|Positive

The call conveyed clear commercial momentum with solid product revenue growth (9% Q4; 10% full-year ex-FX), meaningful unit gains (North America +13% units, rigid +19%), stronger commercial EBITDA and an improving installed base and account penetration (active accounts +22%). Strategic partnerships (Richard Wolf, ForTec, Claritas/ISC) and a healthy cash position support future growth and M&A ambitions. Offsetting these positives were timing-related revenue headwinds from the absence of 2024 milestones, a decline in operating cash flow, one-time COGS adjustments, FX headwinds, earn-out and buyback cash outflows, and uncertainty around regulatory approvals and CMS reimbursement timing. Overall, the positive operational and strategic developments significantly outweigh the near-term financial and timing challenges.View all PHCUF earnings summaries